# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian cancer

Cancer, Ovarian
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 21-30 of 605 results.
The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer Patients
Status: Recruiting
Last Changed: Jan 16, 2017
First Received: Jan 12, 2017
Disease(s): Ovarian Cancer
Locations: National Taiwan University, Taipei, Taiwan
Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer
Status: Recruiting
Last Changed: Nov 13, 2017
First Received: Nov 07, 2017
Disease(s): Ovarian Cancer
Intervention(s): Fludarabine and Pegylated liposomal doxorubicin, Pegylated liposomal doxorubicin
Locations: Sun Yat-sen University Cancer, Guangzhou, Guangdong, China
Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer
Status: Not yet recruiting
Last Changed: Aug 28, 2019
First Received: Aug 28, 2019
Disease(s): Recurrent Platinum-resistant Ovarian Cancer
Intervention(s): Camrelizumab (SHR-1210), Apatinib
Trial in Patients With Relapsed Ovarian Cancer
Status: Recruiting
Last Changed: Oct 31, 2019
First Received: Aug 30, 2017
Disease(s): Ovarian Cancer
Intervention(s): Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562
Locations: VejleSygehus, Vejle, Region Syddanmark, Denmark
Rigshospitalet, København Ø, Sjaelland, Denmark
Tampere University Hospital, Tampere, Finland
Haukeland University Hospital, Bergen, Haukeland, Norway
The Norwegian Radium Hospital, Oslo, Norway
... and 1 other locations.
Evolution of the Therapeutic Care in Ovarian Cancer From 2011
Status: Recruiting
Last Changed: Feb 20, 2019
First Received: Sep 07, 2017
Disease(s): Ovarian Cancer
Locations: Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France
Institut Bergonié, Bordeaux, France
Centre François Baclesse, Caen, France
Centre Jean Perrin, Clermont-ferrand, France
Centre Georges-François Leclerc, Dijon, France
... and 16 other locations.
Phase III Trial of Stage I Ovarian Cancer After Surgery
Status: Recruiting
Last Changed: Aug 30, 2019
First Received: Aug 21, 2019
Disease(s): Epithelial Ovarian Cancer
Intervention(s): adjuvant chemotherapy
Locations: Aichi Medical University Hospital, Nagakute-shi, Aichi, Japan
Tosei General Hospital, Seto-shi, Aichi, Japan
Fujita Health University Hospital, Toyoake-shi, Aichi, Japan
Hirosaki University School of Medicine & Hospital, Hirosaki-shi, Aomori, Japan
The Jikei University School of Medicine Kashiwa Hospital, Kashiwa-shi, Chiba, Japan
... and 99 other locations.
Trial Comparing Niraparib-bevacizumab-TSR042 and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
Status: Not yet recruiting
Last Changed: Jan 17, 2019
First Received: Jan 16, 2019
Disease(s): Ovarian Cancer
Intervention(s): Niraparib, Bevacizumab, TSR042, Carboplatin, Paclitaxel
Locations: NSGO, Copenhagen, Sjaelland, Denmark
Rigshospitalet, Copenhagen, Sjaelland, Denmark
Rigshospitalet, København Ø, Sjaelland, Denmark
Aalborg University Hospital, Aalborg, Denmark
Tampere University Hospital, Tampere, Finland
... and 4 other locations.
Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer
Status: Recruiting
Last Changed: Aug 21, 2018
First Received: Feb 12, 2016
Disease(s): Epithelial Ovarian Cancer
Intervention(s): HIPEC, No HIPEC
Locations: Hospital General Ciudad Real, Ciudad Real, Spain
Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer
Status: Not yet recruiting
Last Changed: Jan 31, 2020
First Received: Nov 04, 2019
Disease(s): Ovarian Cancer Recurrent
Intervention(s): M4344+Niraparib, M4344+Niraparib
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Clinical Pre-screening Protocol for Ovarian Cancer
Status: Recruiting
Last Changed: May 14, 2019
First Received: Mar 18, 2019
Disease(s): Ovarian Cancer
Intervention(s): Drug Response Predictor® (DRP)
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts, United States